Novartis

Nov 29, 2024

Lung cancer, to date, remains the leading cause of death worldwide, however, the epidemiological analysis depicts varying NSCLC incidence all over the world. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths. The number of people living for at least five years after ...

Aug 19, 2024

The first horse bearing Novartis’ IgAN treatment has reached the FDA’s approval milestone. FABHALTA is approved for use in treating IgAN patients who are at risk of swift disease progression, as evidenced by a urine protein-to-creatinine ratio of 1.5 g/g or higher. On August 8, the FDA approved the use of Novart...

Apr 26, 2024

2024 could be an eventful year for LUTATHERA and radioligand therapies (RLTs) around their future commercial prospects.  On April 23, 2024, the FDA approved LUTATHERA (lutetium Lu 177 dotatate) for the treatment of pediatric patients aged 12 years and older with somatostatin receptor (SSTR)-positive gastro-...

Mar 01, 2024

Individuals suffering from food allergies now have access to a medication that can potentially avert serious consequences. This medication, which has been available for twenty years, has received approval from the FDA. Xolair (omalizumab) by Roche and Novartis is the first food allergy treatment sanctioned to dimin...

Jan 26, 2024

A month following Novartis’ foray into the paroxysmal nocturnal hemoglobinuria (PNH) treatment domain, AstraZeneca strengthens its position in this field as its latest contender, Voydeya, secures a groundbreaking approval in Japan. Voydeya (danicopan), an innovative oral factor D inhibitor, has received approval fr...

Jan 17, 2024

From January 8th to 11th, 2024, the 42nd Annual J.P. Morgan Healthcare Conference (JPM24) took center stage in San Francisco, CA, USA. Spanning four dynamic days, this conference saw the active participation of prominent figures from major pharmaceutical, biotechnology, Medtech, HealthTech entities, and emerging fa...

Nov 24, 2023

While another inflammatory biologic is making strides in the hidradenitis suppurativa treatment domain, Cosentyx by Novartis currently holds a significant lead. This advantage is crucial for Swiss Pharma, especially as dermatology experts anticipate strong competition from UCB’s bimekizumab, recently approved as Bi...

Oct 03, 2023

AbbVie Presents Results from Phase III CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma AbbVie has released findings from its Phase III CANOVA trial, which assessed the safety and effectiveness of venetoclax (marketed as VENCLEXTA®/VENCLYXTO®) in combination with dexamethasone ...

Sep 26, 2023

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera On Sept. 20, 2023, Disc Medicine, Inc. (NASDAQ: IRON) announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to MWTX-003 for the treatment of patients with Polycyt...

May 08, 2023

In recent years, the development of cell and gene therapies has provided a new avenue for the treatment of rare disorders. This article will discuss the current and future scenarios of cell and gene therapies in rare disorders with cancer indications as an exception, in Japan. Cell therapy is a treatment in which l...